LPCN Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
-100.0%
1.1M
+899.7%
114.6K
-77.1%
500.0K
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
-100.0%
1.1M
+899.7%
114.6K
-77.1%
500.0K
Operating Expenses
3.0M
-23.6%
4.0M
+8.4%
3.7M
+5.3%
3.5M
+14.8%
3.0M
R&D
2.0M
-26.2%
2.8M
+3.2%
2.7M
-1.1%
2.7M
+26.7%
2.1M
SG&A
991.0K
-17.7%
1.2M
+22.5%
983.4K
+28.1%
767.8K
-13.8%
890.4K
Operating Income
-3032345
+23.6%
-3968861
-57.8%
-2515801
+25.1%
-3361040
-33.0%
-2527202
EBITDA
-3017697
+23.7%
-3954047
-58.1%
-2500820
+25.3%
-3346917
-33.3%
-2511094
Net Income
-2622595
+28.6%
-3671894
-54.9%
-2370084
+25.6%
-3186832
-44.5%
-2205716
EPS (Basic)
$-0.32
+40.7%
$-0.54
-28.6%
$-0.42
+28.8%
$-0.59
-43.9%
$-0.41
EPS (Diluted)
$-0.32
+40.7%
$-0.54
-54.3%
$-0.35
+40.7%
$-0.59
-43.9%
$-0.41
Shares (Diluted)
8.2M
+20.9%
6.8M
+1.1%
6.7M
+24.1%
5.4M
+1.1%
5.4M
Lipocine (LPCN) โ€” Financials